secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2025-01-02T23:59:59+00:00
Accession:  0001420720-25-000001
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio licenses anti-myostatin antibody IBIO-600 from AstralBio; launches bispecific program for obesity
--------------------------------------------------------------------------------

- Upfront payment of $750,000 paid in common stock; milestones up to $28M.
- IBIO-600 is a long-acting anti-myostatin antibody designed for subcutaneous use.
- iBio initiated a bispecific antibody program targeting myostatin/activin A for obesity and cardiometabolic disorders.
- Preclinical studies show potent myostatin inhibition; NHP data expected early 2025.
- Plans to enter clinical trials in obesity and cardiometabolic disorders in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000001/0001420720-25-000001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072025000001/ibio-20241230x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-25-000001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer